Chinook Therapeutics CEO says Novartis acquisition will be good for patients

KDNYDelisted Stock  USD 39.25  0.20  0.51%   
Slightly above 53% of Chinook Therapeutics' investor base is interested to short. The analysis of current outlook of investing in Chinook Therapeutics suggests that many traders are impartial regarding Chinook Therapeutics' prospects. Chinook Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Chinook Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Chinook CEO Eric Dobmeier spent 15 years at Seagen earlier in his career.

Read at bizjournals.com
bizjournals News
  

Chinook Therapeutics Fundamental Analysis

We analyze Chinook Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chinook Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chinook Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Insiders

Shares Owned By Insiders Comparative Analysis

Chinook Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Chinook Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Chinook Therapeutics stock to make a market-neutral strategy. Peer analysis of Chinook Therapeutics could also be used in its relative valuation, which is a method of valuing Chinook Therapeutics by comparing valuation metrics with similar companies.

Peers

Chinook Therapeutics Related Equities

PLRXPliant Therapeutics   2.00   
0%
100.0%
DAWNDay One   1.53   
0%
76.0%
VTYXVentyx Biosciences   1.13   
0%
56.0%
TVTXTravere Therapeutics   0.59   
0%
29.0%
PCVXVaxcyte   0.38   
0%
19.0%
NUVLNuvalent   0.08   
4.0%
0%
ASNDAscendis Pharma   0.18   
9.0%
0%
KALVKalvista Pharmaceuticals   0.30   
15.0%
0%
SWTXSpringWorks Therapeutics   0.60   
30.0%
0%
RNAAvidity Biosciences   0.69   
34.0%
0%
CRNXCrinetics Pharmaceuticals   0.81   
40.0%
0%
ACLXArcellx   1.12   
56.0%
0%
KURAKura Oncology   1.16   
57.0%
0%
RVMDRevolution Medicines   1.25   
62.0%
0%
VRDNViridian Therapeutics   1.46   
73.0%
0%
GPCRStructure Therapeutics   1.78   
89.0%
0%
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Other Consideration for investing in Chinook Stock

If you are still planning to invest in Chinook Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chinook Therapeutics' history and understand the potential risks before investing.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities